Enliven Therapeutics Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
65
- Stock Symbol
-
ELVN
- Investments
-
1
- Share Price
-
$46.53
- (As of Friday Closing)
Enliven Therapeutics General Information
Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Contact Information
Website
www.enliventherapeutics.comCorporate Office
- 205 Park Road
- Burlingame, CA 94010
- United States
Corporate Office
- 205 Park Road
- Burlingame, CA 94010
- United States
Enliven Therapeutics Timeline
Enliven Therapeutics Stock Performance
As of 20-Nov-2026, Enliven Therapeutics’s stock price is $46.53. Its current market cap is $3.42B with 73.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $46.53 | $46.41 | $14.79 - $62.32 | $3.42B | 73.6M | 1.35M | -$1.69 |
Enliven Therapeutics Financials Summary
As of 30-Sep-2026, Enliven Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,464,174 | 436,771 | 807,582 | 307,228 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (135,301) | (119,444) | (103,366) | (83,254) |
| Net Income | (113,482) | (103,694) | (89,024) | (71,584) |
| Total Assets | 897,225 | 476,168 | 325,760 | 271,867 |
| Total Debt | 1,315 | 399 | 0 | 335 |
Enliven Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Enliven Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Enliven Therapeutics Comparisons
Industry
Financing
Details
Enliven Therapeutics Competitors (3)
One of Enliven Therapeutics’s 3 competitors is Tempest Therapeutics, a Formerly VC-backed company based in Brisbane, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tempest Therapeutics | Formerly VC-backed | Brisbane, CA | ||||
| Flare Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Centrose | Venture Capital-Backed | Madison, WI |
Enliven Therapeutics Patents
Enliven Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023154124-A1 | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 | Inactive | 09-Feb-2022 | ||
| WO-2023077259-A1 | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | Inactive | 02-Nov-2021 | ||
| WO-2023081637-A1 | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | Inactive | 02-Nov-2021 | ||
| WO-2023014748-A1 | Nitrated fatty acids for the treatment of sickle cell disorders | Inactive | 03-Aug-2021 | ||
| WO-2022236319-A1 | Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases | Inactive | 07-May-2021 | C07D471/04 |
Enliven Therapeutics Signals
Enliven Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Enliven Therapeutics Acquisitions (1)
Enliven Therapeutics’s most recent deal was a Merger/Acquisition with Imara for . The deal was made on 23-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Imara | 23-Feb-2023 | Merger/Acquisition | Drug Discovery |
Enliven Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Enliven Therapeutics FAQs
-
When was Enliven Therapeutics founded?
Enliven Therapeutics was founded in 2019.
-
Where is Enliven Therapeutics headquartered?
Enliven Therapeutics is headquartered in Burlingame, CA.
-
What is the size of Enliven Therapeutics?
Enliven Therapeutics has 65 total employees.
-
What industry is Enliven Therapeutics in?
Enliven Therapeutics’s primary industry is Drug Discovery.
-
Is Enliven Therapeutics a private or public company?
Enliven Therapeutics is a Public company.
-
What is Enliven Therapeutics’s stock symbol?
The ticker symbol for Enliven Therapeutics is ELVN.
-
What is the current stock price of Enliven Therapeutics?
As of 20-Nov-2026 the stock price of Enliven Therapeutics is $46.53.
-
What is the current market cap of Enliven Therapeutics?
The current market capitalization of Enliven Therapeutics is $3.42B.
-
Who are Enliven Therapeutics’s competitors?
Tempest Therapeutics, Flare Therapeutics, and Centrose are competitors of Enliven Therapeutics.
-
What is Enliven Therapeutics’s annual earnings per share (EPS)?
Enliven Therapeutics’s EPS for 12 months was -$1.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process